AstraZeneca (LON:AZN) Shares Cross Above Two Hundred Day Moving Average – Here’s What Happened

AstraZeneca PLC (LON:AZN) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of £110.18 ($147.21) and traded as high as £126.28 ($168.71). AstraZeneca shares last traded at £125.40 ($167.54), with a volume of 5,091,134 shares traded.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AZN. Shore Capital restated a “buy” rating and set a £145 target price on shares of AstraZeneca in a research report on Tuesday, October 7th. Berenberg Bank lifted their price target on shares of AstraZeneca from £142 to £145 and gave the company a “buy” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a £110 price target on shares of AstraZeneca in a report on Wednesday, July 30th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Monday, October 13th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of £135.

AstraZeneca Trading Down 0.4%

The business’s 50-day moving average is £119.85 and its two-hundred day moving average is £110.18. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The stock has a market capitalization of £193.53 billion, a PE ratio of 23.51, a PEG ratio of 0.86 and a beta of 0.17.

Insiders Place Their Bets

In related news, insider Aradhana Sarin sold 9,563 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of £115.12, for a total transaction of £1,100,892.56. Company insiders own 0.14% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.